Industry leaders are collaborating through InGeNA to quantify the benefits of genomics to Australia and point to a future where precision healthcare is accessible to everyone.
We have started to work with Deloitte Access Economics to develop an evidence base to demonstrate the value of genomics to the economy, society and patient care.
Quantifying the benefits of genomics is central to the InGeNA
Strategic Plan and will be a major contribution to advancing precision health in Australia. InGeNA is openly advocating for patient equity and access to personalised healthcare. The alliance is working with consumer representatives on all programs to ensure a patient-centric approach for all of its activities.
The alliance is also developing strategies around workforce development, advancing industry skills and knowledge of genomics. It’s imperative our workforce is ready to deliver care in the age of precision health. While governments are progressing substantial programs of genomics work, we need an evidence base to establish the right policies and mature data infrastructure to integrate genomics into healthcare.
When it comes to policy and decision-making, we want industry member’s participation into the national agenda.
